Croda Obtains EXCiPACT Certification for Mevisa Site

Jul 29, 2014
By PharmTech Editors

Croda, an excipients supplier, announced that it has obtained EXCiPACT certification for its excipients manufacturing site at Mevisa, Spain.

This certification comes less than six months after Mevisa’s sister site at Rawcliffe Bridge in the UK achieved the same quality accreditation. With this pair of certifications, Croda is now able to offer pharmaceutical customers the benefits of the EXCiPACT scheme over a range of products from two separate manufacturing facilities.

The diverse excipient offering now covered by the certification of these two sites includes industry benchmark ingredients such as Span and Tween surfactants. Croda Mevisa and Rawcliffe Bridge are also home to more recent technologies such as the company’s Crodamol ISIS, a 100% naturally derived emollient ester with a novel method of action. This product works in synergy with the skin’s natural lipid barrier to help reduce transepidermal water loss to maintain an optimum level of skin hydration.

EXCiPACT is a voluntary scheme that reduces the audit burden in the pharmaceutical industry by providing independent third-party certification of manufacturers, suppliers, and distributors of excipients.

Croda is now continuing its global program to gain accreditation at all of its sites that supply pharmaceutical excipients.

Source: Croda